Min Da-liu, Xia Hai-long, Zhou Xiao-yan, Sun Meng-hong, Yang Wen-tao, Zhang Tai-ming, Zheng Ai-hua, Shi Da-ren
Laboratory of Molecular Pathology, Cancer Hospital of Fudan University, Shanghai 200032, China.
Zhonghua Bing Li Xue Za Zhi. 2005 Jun;34(6):327-31.
To investigate bcl-6 protein expression and gene rearrangement patterns in diffuse large B-cell lymphoma (DLBCL) and their clinicopathologic significance.
Immunohistochemical studies for bcl-6 and CD10 proteins were performed on 51 cases of DLBCL paraffin-embedded tissues (including 22 nodal samples and 29 extranodal samples) and 10 cases of reactive lymphoid hyperplasia (RLH) paraffin-embedded tissues. Interphase fluorescence in-situ hybridization (FISH) with dual color breakapart probe was also used to identify rearrangement of bcl-6 gene in 32 cases of nodal DLBCL tissues (including 22 paraffin-embedded samples and 10 fresh samples) and 5 cases of RLH paraffin-embedded tissues.
(1) The rates of bcl-6 protein expression in nodal DLBCL, extranodal DLBCL and RLH were 72.7% (16/22), 75.9% (22/29) and 100.0% (10/10) respectively. The rates of CD10 expression were 40.9% (9/22), 41.4% (12/29) and 100.0% (10/10) respectively. All lymphoma samples which expressed CD10 also showed co-expression of bcl-6 protein. (2) The co-expression of bcl-6 and CD10 was observed in 40.9% (9/22) nodal DLBCL and 41.4% (12/29) extranodal DLBCL. Low clinical stage (stage I and II) was more frequently observed in cases with co-expression of bcl-6 and CD10 (P < 0.05). (3) The rates of bcl-6 gene rearrangement in nodal DLBCL was 28.1% (9/32), with 27.3% (6/22) in paraffin-embedded tissues and 30.0% (3/10) in fresh tissues. There was no statistically significant difference found between the two groups (P > 0.05). Bcl-6 gene rearrangement was not found in all the 5 cases of RLH, and there was a significant difference between RLH and DLBCL (P < 0.05).
The rate of bcl-6 protein expression is high in DLBCL cases, and the detection of bcl-6 and CD10 protein co-expression may help in the diagnosis and differential diagnosis of DLBCL. Those DLBCL cases with co-expression of bcl-6 and CD10 may also have a better prognostic implication. On the other hand, bcl-6 gene rearrangement can be identified by interphase FISH with dual color breakapart probe in both paraffin-embedded and fresh lymphoma tissues.
探讨弥漫性大B细胞淋巴瘤（DLBCL）中bcl-6蛋白表达及基因重排模式及其临床病理意义。
对51例DLBCL石蜡包埋组织（包括22例淋巴结样本和29例结外样本）及10例反应性淋巴组织增生（RLH）石蜡包埋组织进行bcl-6和CD10蛋白的免疫组织化学研究。还采用双色分离探针间期荧光原位杂交（FISH）技术检测32例淋巴结DLBCL组织（包括22例石蜡包埋样本和10例新鲜样本）及5例RLH石蜡包埋组织中bcl-6基因重排情况。
（1）淋巴结DLBCL、结外DLBCL和RLH中bcl-6蛋白表达率分别为72.7%（16/22）、75.9%（22/29）和100.0%（10/10）。CD10表达率分别为40.9%（9/22）、41.4%（12/29）和100.0%（10/10）。所有表达CD10的淋巴瘤样本均同时表达bcl-6蛋白。（2）40.9%（9/22）的淋巴结DLBCL和41.4%（12/29）的结外DLBCL中观察到bcl-6与CD10共表达。bcl-6与CD10共表达的病例中临床分期较低（Ⅰ期和Ⅱ期）更为常见（P<0.05）。（3）淋巴结DLBCL中bcl-6基因重排率为28.1%（9/32），石蜡包埋组织中为27.3%（6/22），新鲜组织中为30.0%（3/10）。两组间差异无统计学意义（P>0.05）。5例RLH中均未发现bcl-6基因重排，RLH与DLBCL之间差异有统计学意义（P<0.05）。
DLBCL病例中bcl-6蛋白表达率较高，检测bcl-6与CD10蛋白共表达有助于DLBCL的诊断及鉴别诊断。bcl-6与CD10共表达的DLBCL病例可能也具有较好的预后意义。另一方面，采用双色分离探针间期FISH技术可在石蜡包埋及新鲜淋巴瘤组织中检测到bcl-6基因重排。
Zotero 插件